Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

109
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
109
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

139
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
139
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

89
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
89
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

308
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
308
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

128
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
128
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mini-invasive Anterior Petrosal Intertentorial Approach for Trigeminal Neuralgia: Rationale and Limits of the Technique.

Journal of neurological surgery. Part B, Skull base·2026
Same author

CIMT 2023: report on the 20th Annual Meeting of the Association for Cancer Immunotherapy.

Immuno-oncology technology·2023
Same author

Comparison of disease severity in glaucoma patients identified by screening in the 1990s and in routine clinical care in the 2010s in Sweden.

Acta ophthalmologica·2023
Same author

Combined petrosal approach: a systematic review and meta-analysis of surgical complications.

Neurosurgical review·2023
Same author

Genomic loci associated with performance limiting equine overriding spinous processes (kissing spines).

Research in veterinary science·2022
Same author

The organisational response of a hospital critical care service to the COVID-19 pandemic: The Groote Schuur Hospital experience.

The Southern African journal of critical care : the official journal of the Critical Care Society·2022

Related Experiment Video

Updated: Mar 28, 2026

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
08:53

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Published on: March 28, 2025

852

How does a drug-coated balloon work? Overview about coating technologies and their impact.

U Speck1, N Stolzenburg, D Peters

  • 1Experimental Radiology, Department of Radiology, Charité, Berlin, Germany - ulrich.speck @charite.de.

The Journal of Cardiovascular Surgery
|December 19, 2015
PubMed
Summary

Drug-coated balloons (DCB) deliver paclitaxel effectively to lesions. Studies show paclitaxel adheres to the balloon, transfers to the vessel wall, and slowly dissolves, inhibiting neointimal proliferation with good tolerance.

More Related Videos

Monitoring the Wall Mechanics During Stent Deployment in a Vessel
08:28

Monitoring the Wall Mechanics During Stent Deployment in a Vessel

Published on: May 8, 2012

9.7K
Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

9.6K

Related Experiment Videos

Last Updated: Mar 28, 2026

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
08:53

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Published on: March 28, 2025

852
Monitoring the Wall Mechanics During Stent Deployment in a Vessel
08:28

Monitoring the Wall Mechanics During Stent Deployment in a Vessel

Published on: May 8, 2012

9.7K
Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

9.6K

Area of Science:

  • Vascular medicine
  • Biomaterials science
  • Pharmacology

Background:

  • Drug-coated balloons (DCB) deliver antineoplastic agents, such as paclitaxel, to target lesions.
  • Understanding paclitaxel's behavior and efficacy in DCB is crucial for vascular interventions.

Purpose of the Study:

  • To review literature and experimental data on the delivery, retention, and effects of paclitaxel from DCB.
  • To evaluate the efficacy and safety of paclitaxel-coated balloons in preclinical models.

Main Methods:

  • Literature review of DCB technology and preclinical studies.
  • Experimental simulations of DCB deployment and in vivo studies in pigs.

Main Results:

  • Paclitaxel adheres to the balloon, with some loss during delivery. Upon inflation, it transfers to the vessel wall, dissolving slowly over approximately 2 months.
  • Formulation impacts drug loss; approximately 10% is lost before the lesion, 5-20% transfers to the vessel wall, and 10% remains on the balloon.
  • DCB demonstrated reliable inhibition of neointimal proliferation in animal models, comparable to drug-eluting stents, with dose-dependent downstream effects but no clinical symptoms.

Conclusions:

  • Paclitaxel is the preferred drug for DCB, with optimal dosing between 2 and 3.5 μg/mm².
  • Overlapping balloon usage showed no adverse effects in preclinical or clinical settings.
  • Future research aims to enhance DCB efficacy for conditions like calcified vessels and expand their application to new territories.